Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Early phase III enrollment for extended-release Eligard

Oct. 3, 2002

Integrin antagonists covered by 3-Dimensional patent

Oct. 3, 2002

New metal complexes as prodrugs of antitumor compounds

Oct. 3, 2002

Geron receives award for ongoing development of telomerase inhibitors for cancer

Oct. 3, 2002

Benefit:risk ratio of tamoxifen for breast cancer prophylaxis evaluated in large trial

Oct. 3, 2002

Iseganan fails to meet primary endpoint in ulcerative oral mucositis phase III trial

Oct. 2, 2002

Orphan drug grant for Endostatin trial

Oct. 2, 2002

Idec gains license to develop HMN-214

Oct. 2, 2002

Vical updates progress of Leuvectin program

Oct. 2, 2002

Novel cytokine and T-cell production inhibitors and their use in cancer, arthritis, etc.

Oct. 2, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...